JUL 3 0 2004 C

FW

3 0 2004		PTO/SB/21 (02-04) Approved for use through 07/31/2006. OMB 0651-0031
Uncoune Paperwork Reduction Act of 1995, no pr	ersons are required to respond to a collection	and Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.
OF MARK	Application Number	10/767,784
TRANSMITTAL	Filing Date	January 29, 2004
FORM	First Named Inventor	Guido Galley
(to be used for all correspondence after initial filing)	Art Unit	1614
(to be deed to: all correspondence and militar mility)	Examiner Name	
	Attack Desirable and an	
Total Number of Pages in This Submission	Attorney Docket Number	21453 US
E	NCLOSURES (Check all that	арріу)
Fee Transmittal Form	Drawing(s)	After Allowance communication to Group
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences
Amendment/Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a	Proprietary Information
Alter Final	Provisional Application Power of Attorney, Revocation	
Affidavits/declaration(s)	☐ Change of Correspondence Addre	
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for Refund	
Information Disclosure Statement	CD, Number of CD(s)	
I R	emarks	
Certified Copy of Priority Document(s)	Cited Referenc	
· · ·		
Response to Missing Parts/ Incomplete Application	PCT Written Op	oinion
Response to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNATUR	RE OF APPLICANT, ATTORNE	Y OR AGENT
Firm	CO A LIGANI, A TONNE	- I, OK AGENT
or Individual name Kimberly J. Prior	\sim	
Signature Tombell	Affred	
Date 22 Buly 3	1604	
CERT	IFICATE OF TRANSMISSION	MAILING
		deposited with the United States Postal Service with ents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name Kimberly J. P	Prior	
Signature Zimk	redu Arion	Date 7-27-04
This collection of information is required by 37 CFR 1.5. 1 process) an application. Confidentiality is governed by 35	The information is required to obtain or retain	n a benefit by the public which is to file (and by the USPTO to

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C._122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Guido Galley et al Group: 1614

Serial No. 10/767,784, filed January 29, 2004 Examiner:

(Reference No. 21453 US)

For: MALONAMIDE DERIVATIVES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 Date: July 27, 2004

Mail Stop: Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Documents B1-B2 and C11 listed on Form PTO-1449 are enclosed.

Document B1, which is not written in the English language, is abstracted in Document B1(a).

Enclosed is a PCT Written Opinion of the International Searching Authority, dated June 28, 2004, which was issued by the European Patent Office in application PCT/EP2004/000674 corresponding to the captioned application. The PCT Written Opinion lists Documents B1-B2 and C11.

Serial No. 10/767,784

Filed: January 29, 2004

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Supplemental Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application and/or because each item of information contained in the Information Disclosure Statement was cited in a communication for the first time from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior

(Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

144470

6	1 6	$\overline{}$		Substitute	for form 1449A/PTO	Comp	lete if Kno	wn	
/ 0	• •	(4)	INFORM	ATIO	N DISCLOSURE	Application Number	10/767,	10/767,784	
/		راي ا	STATEM	ENT E	BY APPLICANT	Filing Date	January	29, 2004	
JUL	3 0	2004 🖭				First Name Inventor	Guido C	Galley	
			(Use se	veral she	ets if necessary)	Group Art Unit	1614		
		A				Examiner Name			
A PA	DENE	neet	1	of	1	Attorney Docket Number	21453	US	
	U.S. PATENT DOCUMENTS								
				Ţ	J.S. Patent Document				
		Examino Initials'			Kind Code	Name of Patentee or Ap	•	Date of Publication of Cited document	

Examiner Initials'	Cite No.¹	Number		Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited docume MM-DD-YY	nt
		ļ					
		ļ					
		<u> </u>					
	ļ	ļ				_	
				DELCHIPA			
	l	FOREIGN PA' Foreign Patent Document			TENT DOCUMENTS	Date of	T ^e
Examiner Initials'	Cite No.'	Office ³	Number	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Publication of Cited Document MM-DD-YYYY	•
	B1	WO 9:	3/03011	A1	YAMANOUCHI PHARM CO LTD	02-18-1993	1
	B2	WO 0	1/27091	A1	DU PONT PHARMACEUTICALS CO.	04-19-2001	
				· · ·			
Examiner Signature		Date Cor	nsidered		•		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. *See attached Kinds of U.S. Patent Documents. *JEnter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation or abstract is attached.

Substitute for form 1449A/PTO			or form 1449A/PTO	Complete if Known		
I	NFORMA	TION	DISCLOSURE	Application Number	10/767,784	
S	TATEME	NT B	Y APPLICANT	Filing Date	January 29, 2004	
				First Name Inventor	Guido Galley	
1	(Use seve	eral shee	ets if necessary)	Group Art Unit	1614	
				Examiner Name		
Sheet	2	of	2	Attorney Docket Number	21453 US	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials'	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C11	H.F. DOVEY et al, Journal of Neurochemistry, Vol. 76, No. 1,	
	_	pp. 173-181 (2001)	
			
	1		
			<u> </u>
	_		
	-		
	-		
Examiner		DATE	l
Signature		CONSIDERED CONSIDERED	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Unique citation designation number. Applicant is to place a check mark here if English language Translation or abstract is attached.

144469